Shares of Sakar Healthcare Ltd rallied 4% on Friday, 7 November, after the company announced securing marketing approval for 9 drugs. 

In its regulatory filing, Sakar Healthcare announced securing 9 new marketing approvals for its oncology (cancer) drugs in Europe and emerging regions, increasing the total number to 11. The approval documents cover key medications such as carboplatin, docetaxel, irinotecan, gemcitabine, tamoxifen, and abiraterone, which are widely used in the treatment of cancer.

These approvals will allow Sakar to distribute anti-cancer drugs throughout Europe, Latin America, and Southeast Asia. The company manufactures these drugs at its own EU-GMP-certified facility and plans to obtain further licenses in the coming months, enhancing export possibilities and cementing its global footprint in the oncology field.

Sakar Healthcare Limited is an Indian pharmaceutical firm that specialises in the research, development, and commercialisation of a wide range of pharmaceuticals.  

Their product portfolio includes pills, capsules, syrups, injections, and dry powders, which address a variety of health concerns such as pain alleviation, infections, mental health, digestion, and more. They also export their products to Southeast Asia, Africa, the MENA region, and the United States.

However, at 2:02 pm, the shares of Sakar Healthcare shed all their early gains and were trading 2.94% lower at Rs 378.60 on NSE. 

Feeling overwhelmed by the markets? Let Unicorn Signals be your guide. Our user-friendly app simplifies complex data and provides actionable trading signals. Download the app today and trade with confidence!